Values First Advisors Inc. Purchases 4,604 Shares of Guardant Health, Inc. (NASDAQ:GH)

Values First Advisors Inc. boosted its position in Guardant Health, Inc. (NASDAQ:GH) by 15.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 35,135 shares of the company’s stock after purchasing an additional 4,604 shares during the period. Values First Advisors Inc.’s holdings in Guardant Health were worth $950,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in GH. CWM LLC increased its position in shares of Guardant Health by 137.1% during the third quarter. CWM LLC now owns 984 shares of the company’s stock worth $29,000 after acquiring an additional 569 shares during the period. BluePath Capital Management LLC purchased a new position in shares of Guardant Health during the third quarter worth approximately $35,000. Acadian Asset Management LLC purchased a new position in shares of Guardant Health during the first quarter worth approximately $37,000. Captrust Financial Advisors increased its position in shares of Guardant Health by 33.2% during the second quarter. Captrust Financial Advisors now owns 1,087 shares of the company’s stock worth $44,000 after acquiring an additional 271 shares during the period. Finally, Belpointe Asset Management LLC increased its position in shares of Guardant Health by 33.3% during the first quarter. Belpointe Asset Management LLC now owns 3,049 shares of the company’s stock worth $71,000 after acquiring an additional 761 shares during the period. Institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Guggenheim assumed coverage on shares of Guardant Health in a report on Thursday, December 14th. They set a “neutral” rating on the stock. Wolfe Research initiated coverage on shares of Guardant Health in a report on Wednesday, December 13th. They issued a “peer perform” rating on the stock. JPMorgan Chase & Co. cut their price target on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating on the stock in a report on Friday, February 23rd. Canaccord Genuity Group cut their price target on shares of Guardant Health from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Friday, February 23rd. Finally, Piper Sandler cut their price target on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, February 26th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $41.30.

Guardant Health Stock Performance

Shares of NASDAQ:GH traded up $2.67 on Friday, hitting $20.63. 5,569,146 shares of the company were exchanged, compared to its average volume of 1,669,355. The stock’s 50 day moving average price is $20.56 and its 200 day moving average price is $24.44. Guardant Health, Inc. has a 1-year low of $16.92 and a 1-year high of $41.06. The company has a current ratio of 6.54, a quick ratio of 6.24 and a debt-to-equity ratio of 7.18.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.65). The business had revenue of $155.05 million for the quarter, compared to analyst estimates of $151.71 million. Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. Equities analysts expect that Guardant Health, Inc. will post -3.49 earnings per share for the current year.

Insider Activity at Guardant Health

In other news, insider Kumud Kalia acquired 2,187 shares of the business’s stock in a transaction on Monday, March 18th. The stock was bought at an average price of $17.82 per share, with a total value of $38,972.34. Following the completion of the acquisition, the insider now owns 12,722 shares of the company’s stock, valued at $226,706.04. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.20% of the stock is currently owned by insiders.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.